Gilead Sciences, Inc. (NASDAQ:GILD) had its target price upped by Mizuho from $77.00 to $83.00 in a report issued on Wednesday morning. Mizuho currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms also recently weighed in on GILD. BMO Capital Markets reiterated a hold rating and set a $82.00 target price on shares of Gilead Sciences in a research report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company a buy rating in a research report on Wednesday, October 25th. Needham & Company LLC reiterated a hold rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr upgraded Gilead Sciences from a hold rating to a buy rating and set a $89.27 target price on the stock in a research report on Wednesday, September 6th. Finally, Morgan Stanley reiterated an equal weight rating and set a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. Gilead Sciences currently has an average rating of Buy and an average price target of $85.92.
Gilead Sciences (GILD) traded up $0.75 during mid-day trading on Wednesday, hitting $73.77. The stock had a trading volume of 7,698,200 shares, compared to its average volume of 9,244,684. The stock has a market cap of $96,363.46, a P/E ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a current ratio of 3.68, a quick ratio of 4.74 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the business earned $2.75 earnings per share. sell-side analysts expect that Gilead Sciences will post 8.53 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/12/gilead-sciences-inc-gild-price-target-increased-to-83-00-by-analysts-at-mizuho.html.
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.82%. Gilead Sciences’s payout ratio is 23.69%.
In related news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares in the company, valued at $3,684,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at approximately $8,945,723. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,269,486 in the last quarter. 1.30% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its holdings in shares of Gilead Sciences by 1.9% in the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. raised its stake in Gilead Sciences by 2.4% in the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after buying an additional 310,607 shares in the last quarter. FMR LLC raised its stake in Gilead Sciences by 1.1% in the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. Hedge funds and other institutional investors own 74.38% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.